Metabolic response behind reduced cancer cell growth
2021-02-12
Researchers from IGP show in a new study that inhibition of the protein EZH2 can reduce the growth of cancer cells in the blood cancer multiple myeloma. The reduction is caused by changes in the cancer cells’ metabolism. These changes can be used as markers to discriminate whether a patient would respond to treatment by EZH2 inhibition. The study has been published in the journal Cell Death & Disease.
Multiple myeloma is a type of blood cancer where immune cells grow in an uncontrolled way in the bone marrow. The disease is very difficult to treat and is still considered to be incurable, and thus it is urgent to identify new therapeutic targets in the cancer cells.
The research group behind the new study has previously shown that cultivated multiple myeloma cells had reduced growth and were even killed if they were treated with a substance that inhibited the EZH2 protein. Now they found that EZH2 inhibition also reduced cancer growth in a multiple myeloma mouse model.
“We treated mice with a type of cancer that corresponds to human multiple myeloma with a substance that inhibits EZH2 and discovered several signs that the treated mice had a slower cancer growth than non-treated mice. This provided further evidence for the potential of EZH2 as a target for clinical intervention,” says Helena Jernberg Wiklund, who has led the study.
The results from the mouse model encouraged the researchers to further investigate what it is that makes the cells sensitive to EZH2 inhibition. Human multiple myeloma cells are more heterogenous than mouse model cells and they found that some types of human cultivated multiple myeloma cells were sensitive whereas others were resistant.
To study this phenomenon further, the researchers employed a global analysis of cellular metabolites in combination with analysis of gene activity. Sensitivity was found to be associated with alterations in specific metabolic pathways in the cells.
“In cells that were sensitive to EZH2 inhibition, the methionine cycling pathways were altered, an effect we did not detect in non-sensitive cells. This alteration was caused by a down-regulation of methionine cycling-associated genes, says Helena Jernberg Wiklund.
The alterations in metabolite abundance in the methionine cycling pathways could be used as markers to discriminate whether a patient is responding to EZH2 inhibition, which is of great importance for the potential clinical use of this treatment.
“Our findings provide an increased understanding of the mechanisms behind the sensitivity of multiple myeloma cells to EZH2 inhibition. They also highlight that global analysis of metabolites and gene activity are powerful tools and when used together, they provide a better understanding of what happens in cancer cells when exposed to novel treatments. We believe that our results are relevant to both preclinical and clinical researchers, as a step towards finding new ways to treat patients with multiple myeloma,” says Helena Jernberg Wiklund.
More information:
Paper in Cell Death & Disease
Helena Jernberg Wiklund’s research
-
Beta blockers can repair malformed blood vessels in the brain
2021-02-23
Propranolol, a drug that is efficacious against infantile haemangiomas (“strawberry naevi”, resembling birthmarks), can also be used to treat cerebral cavernous malformations, a condition characterised by misshapen blood vessels in the brain and elsewhere. This has been shown by IGP researchers in a new study published in the scientific journal Stroke.
-
Innate immune system aggravates severe COVID-19
2021-02-23
In critically ill COVID-19 patients, the innate immune system is strongly activated which can cause thrombosis and reduced oxygenation in the patients. This is shown in a study from IGP, published in the journal Frontiers in Immunology.
-
Metabolic response behind reduced cancer cell growth
2021-02-12
Researchers from IGP show in a new study that inhibition of the protein EZH2 can reduce the growth of cancer cells in the blood cancer multiple myeloma. The reduction is caused by changes in the cancer cells’ metabolism. These changes can be used as markers to discriminate whether a patient would respond to treatment by EZH2 inhibition. The study has been published in the journal Cell Death & Disease.
-
Increased cancer risk in children of mothers with thyroid disorders
2021-01-21
Thyroid disorders in mothers-to-be increases the risk for future thyroid cancer in the children. This is shown in a new study in the journal The Lancet Diabetes & Endocrinology where IGP researcher Ingrid Glimelius has participated.
-
Disrupted immune cell navigation in lymph nodes of breast cancer patients
2021-01-12
Different types of breast cancer tumours differ in how they affect the function of the lymph nodes. In patients with invasive breast cancer, the vessels and supporting tissue of the lymph nodes are altered, which cannot be seen in patients with a non-invasive cancer called (ductal cancer in situ). This is shown in a new study from Maria Ulvmar’s group at IGP, published online in the scientific journal Cancers.
-
Oral contraceptive pills protect against ovarian and endometrial cancer
2020-12-17
A comprehensive study from Uppsala University, involving more than 250,000 women, shows that oral contraceptive use protects against ovarian and endometrial cancer. The protective effect remains for several decades after discontinuing the use. The study is published in the journal Cancer Research.
-
Vener bakom blodkärlsmissbildningar i hjärnan
2020-11-03
In the condition known as cavernoma, lesions arise in a cluster of blood vessels in the brain, spinal cord or retina. Researchers in Elisabetta Dejana's group at IGP can now show, at molecular level, that these changes originate in vein cells. This new knowledge of the condition creates potential for developing better therapies for patients. The study has been published in the journal eLife.
-
World’s largest ever DNA sequencing of Vikings
2020-09-16
Genetic examinations of more than 400 Viking age skeletons reveal that the Vikings that raided Europe came from relatively isolated groups in Scandinavia and many of them had a genetic influx from Asia or Southern Europe. This is presented in a study in the journal Nature, in which Marie Allen and Magdalena Bus from IGP have participated.
-
Internet-based support can reduce depressions symptoms in cancer patients
2020-09-14
The internet can be used to provide education and support for self-management interventions to alleviate depression symptoms in individuals with cancer. This is shown in a study from Birgitta Johansson’s group at IGP.
-
Leakage from blood and lymphatic vessels is differently regulated
2020-09-09
Researchers from IGP show in a new study that cell signalling regulating vessel leakage differs between blood and lymphatic vessels. The findings suggest a possibility to modulate this signalling in order to selectively control lymphatic vessel function and to treat diseases characterised by lymphatic vessel leakage.
-
New early biomarker for several cancer diseases
2020-08-26
In a study including more than 400 hospital patients with 18 different cancer diagnoses, researchers have been able to show that EVP, extracellular vesicles and particles, could be used as biomarkers for several cancer diseases. The study has been led by researchers from among others IGP.
-
New findings on enzymes with important role in SARS-CoV-2 infection
2020-08-17
Researchers at IGP have described the presence, throughout the human body, of the enzyme ACE2. This is thought to be the key protein used by the SARS-CoV-2 virus for host cell entry and development of the disease COVID-19. In contrast to previous studies, the study shows that no or very little ACE2 protein is present in the normal respiratory system. The results are presented in Molecular Systems Biology.
-
Unexpected associations found between drug response and cell changes in brain cancer
2020-07-15
Therapies for treating glioblastoma brain cancer can be delivered with greater precision and existing drugs can be used in new ways. These are the conclusions from a study from IGP investigating a large number of cell samples from patients with brain tumours. The researchers have characterised how changes in glioblastoma cells influence the effect of different drugs. Their findings are published in the journal Cell Reports.
-
New method to identify genes that can drive development of brain tumors
2020-06-09
Researchers at Uppsala University have developed a method for identifying functional mutations and how these affect genes with significance for the development of glioblastoma – a malignant brain tumor with very poor prognosis. The study is published in Genome Biology.
-
New effective way to inhibit lymphatic malformations
2020-06-08
Lymphatic malformation is a debilitating and often incurable disease. Taija Mäkinen’s research group has in an international collaboration studied cellular mechanisms leading to abnormal vessel growth and identified a combination therapy that may allow effective treatment of these malformations.
-
Lymphatic vessels in mice and humans: alike yet different
2020-05-04
In an international collaboration, researchers from IGP have mapped the lymph node lymphatic vessels in mice and humans down to the level of individual cells. The results may eventually help scientists to discover new methods for strengthening the immune system against viruses and cancer. Their work has been published in the journal Frontiers of Cardiovascular Research.
-
Scientists identify cause of leakiness in eye diseases
2020-04-22
Targeting a molecule that contributes to leaky eye vessels, while sparing nerve and blood-vessel cells, could be a safer treatment strategy for age and diabetes-related vision loss. Scientists at IGP have identified a key step in the process that leads to leaky vessels and harmful swelling in eye diseases, according to a new study published today in the journal eLife.
-
Changes in cellular degradation hubs can lead to cancer
2020-03-17
Cancer cells grow and divide in an uncontrolled manner. A new study from IGP now shows how alterations in a cell’s degradation hubs, called lysosomes, can cause abnormal cell growth. The results are published today in the scientific journal Nature Communications.
-
Careless cancer cells may be susceptible to future drugs
2020-03-12
Could the ability of cancer cells to quickly alter their genome be used as a weapon against malignant tumours? Researchers at IGP have succeeded in developing a substance that has demonstrated promising results in experiments on both animal models and human cancer cells. The study is published in the journal Nature Communications.
-
Smart algorithm finds possible future treatment for childhood cancer
2020-01-07
Using a computer algorithm, scientists at IGP have identified a promising new treatment for neuroblastoma. This form of cancer in children, which occurs in specialised nerve cells in the sympathetic nervous system, may be life-threatening. In the long term the discovery, described in the latest issue of the scientific journal Nature Communications, may result in a new form of treatment for children in whom the disease is severe or at an advanced stage.